A Lesson in Data Analysis – Brand Management 133
Torrent Pharma was understandably excited when many observers celebrated its impressive 38% market share in the semaglutide segment during the very first month. Such enthusiasm is natural. But the story of a brand is rarely written in a single month. What happened in the second month? And what will the third month reveal? Time will tell.
What deserves equal attention is not merely market share, but the metric that ultimately determines long-term success, prescriptions. That is why the companies behind Wegovy and Foundayo are closely tracking weekly prescription trends, as shown in the graph. They understand that sustained prescription growth, not early celebrations, is what creates enduring brands.
The lesson is clear. Comprehensive data analysis is no longer optional; it is an imperative. Looking at only one indicator can create an illusion of success. In 2026, pharmaceutical marketers need a far broader and deeper understanding of the market than what was considered adequate in the 1970s and 1980s. The tools, the speed of change, and the competitive landscape have all changed.
And by 2040 or 2047, the rules of the game may change yet again. Yesterday’s methods cannot be expected to solve tomorrow’s challenges. Those who continue to rely on outdated approaches may find themselves celebrating numbers that tell only part of the story.
There is, however, a timeless lesson hidden in all this.
Aesop’s fable of the tortoise and the hare remains as relevant in pharmaceutical marketing as ever. The hare had speed, excitement, and the advantage of a fast start. The tortoise had patience, discipline, and consistency. In the end, it was not the fastest beginning that mattered, but the ability to keep moving forward.
Brands are no different.
In pharmaceutical marketing, enduring success is built not by celebrating the first month’s market share, but by patiently earning prescriptions; month after month, quarter after quarter, and year after year.
The tortoise still wins, not because it is slow, but because it never stops.
And perhaps that is the most important lesson for pharmaceutical marketers in 2026, and indeed in 2040 or 2047: the winners are seldom those who generate the loudest excitement at the start, but those who patiently build momentum and sustain it, prescription after prescription.
For the full story on Wegovy Foundayo race, please log on to: The Oral GLP-1 Tracker: Week 1 of Lilly’s Foundayo launch